2023 - Research.com Chemistry in Austria Leader Award
2022 - Research.com Chemistry in Austria Leader Award
Ruthenium, Stereochemistry, Cisplatin, Ligand and Platinum are his primary areas of study. His Ruthenium research incorporates elements of Indazole, Medicinal chemistry and Metal. Particularly relevant to Nuclear magnetic resonance spectroscopy is his body of work in Stereochemistry.
His Cisplatin study combines topics in areas such as Cancer, Cancer chemotherapy, Cancer research, Oxaliplatin and Pharmacology. The various areas that Bernhard K. Keppler examines in his Ligand study include Biological activity, Lipophilicity, Reactivity and Aquation. Bernhard K. Keppler has researched Platinum in several fields, including Inductively coupled plasma mass spectrometry, Prodrug and Chromatography, Capillary electrophoresis.
The scientist’s investigation covers issues in Stereochemistry, Ruthenium, Platinum, Medicinal chemistry and Ligand. His Stereochemistry study incorporates themes from In vitro, Cytotoxicity and Cisplatin. His study in Cisplatin is interdisciplinary in nature, drawing from both Cancer research, Oxaliplatin and Pharmacology.
The Ruthenium study which covers Indazole that intersects with Imidazole. Bernhard K. Keppler focuses mostly in the field of Platinum, narrowing it down to topics relating to Chromatography and, in certain cases, Blood proteins. The concepts of his Medicinal chemistry study are interwoven with issues in Organic chemistry and Crystal structure.
Bernhard K. Keppler mostly deals with Ligand, In vivo, Stereochemistry, Ruthenium and Aqueous solution. Within one scientific family, Bernhard K. Keppler focuses on topics pertaining to Cytotoxicity under Ligand, and may sometimes address concerns connected to Nuclear magnetic resonance spectroscopy. His research integrates issues of Sample preparation, Biochemistry, Serum albumin and Pharmacology in his study of In vivo.
His studies in Stereochemistry integrate themes in fields like DNA, Cytotoxic T cell and Medicinal chemistry. His Ruthenium study which covers Combinatorial chemistry that intersects with Prodrug. His Aqueous solution research is multidisciplinary, incorporating elements of Nuclear chemistry, Inorganic chemistry, Leaching, Ionic liquid and Metal.
His main research concerns In vivo, Ruthenium, Stereochemistry, DNA and Platinum. His In vivo research is multidisciplinary, relying on both Transferrin, Serum albumin, Cisplatin and Chloride. His Ruthenium research includes elements of Moiety, Metal and Molecular targets.
In his study, which falls under the umbrella issue of Stereochemistry, Redox, Lipophilicity, Cytotoxic T cell and Ic50 values is strongly linked to Ligand. His research integrates issues of Nuclear chemistry, Coordination sphere, Oxaliplatin, Prodrug and Nuclear magnetic resonance spectroscopy in his study of Platinum. His Oxaliplatin research is multidisciplinary, incorporating elements of In vitro, Cytotoxicity, Reactivity, Flow cytometry and Pharmacology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
From bench to bedside – preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A)
Christian G. Hartinger;Stefanie Zorbas-Seifried;Michael A. Jakupec;Bernd Kynast.
Journal of Inorganic Biochemistry (2006)
KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients.
Christian G. Hartinger;Christian G. Hartinger;Michael A. Jakupec;Stefanie Zorbas‐Seifried;Michael Groessl.
Chemistry & Biodiversity (2008)
Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches.
Markus Galanski;Michael A. Jakupec;Bernhard K. Keppler.
Current Medicinal Chemistry (2005)
Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology.
Andrei R Timerbaev;Christian G Hartinger;Svetlana S Aleksenko;Bernhard K Keppler.
Chemical Reviews (2006)
Antitumour metal compounds: more than theme and variations.
Michael A. Jakupec;Markus Galanski;Vladimir B. Arion;Christian G. Hartinger.
Dalton Transactions (2008)
Recent Developments in the Field of Tumor-Inhibiting Metal Complexes
M. Galanski;V. B. Arion;M. A. Jakupec;B. K. Keppler.
Current Pharmaceutical Design (2003)
NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application
Robert Trondl;Petra Heffeter;Christian R. Kowol;Michael A. Jakupec.
Chemical Science (2014)
Metal complexes in cancer chemotherapy
Bernhard K. Keppler.
Tumour-inhibiting platinum complexes--state of the art and future perspectives.
M. A. Jakupec;M. Galanski;B. K. Keppler.
Reviews of Physiology Biochemistry and Pharmacology (2003)
Anticancer activity of metal complexes: involvement of redox processes.
Ute Jungwirth;Christian R. Kowol;Bernhard K. Keppler;Christian G. Hartinger.
Antioxidants & Redox Signaling (2011)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: